Cetrelimab is a monoclonal antibody targeting the PD-1 receptor, used primarily in cancer immunotherapy. It works by blocking the interaction between PD-1 and its ligands PD-L1 and PD-L2, thereby enhancing the immune system’s ability to recognize and destroy tumor cells. It is applied in the treatment of advanced solid tumors, including non-small cell lung cancer and melanoma. By reactivating exhausted T-cells, cetrelimab helps sustain anti-tumor immune responses. It is often used in combination with other immunotherapies or chemotherapies to improve clinical outcomes. Ongoing studies explore its efficacy in hematologic malignancies and as a neoadjuvant or adjuvant therapy.